Valeo Pharma Inc VPHIF

Healthcare

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

GREY:VPHIF - Post by User

Valeo Pharma Inc > Q3 highlights

<< Previous

Bullboard Posts

Next >>

Post by kooter33on Oct 07, 2020 11:39am

213 Views

Post# 31680070

Q3 highlights

"The third quarter was very much in line with the second quarter after taking into consideration the non-recurrent nature of a number of items impacting our third quarter. We expect to see key operational metrics continuing their improvement and positioning Valeo to exit Q4-2020 as a profitable EBITDA company", added Mr. Mainville.
This statement by the CFO keeps me in the game and wanting more at these prices. YE is Oct 31st 2020. I will wait to see where this bottoms out before adding. So much volatility in the markets right now. Much of that will be settled when the Presidential elections are over and new US President is elected. Who knows when that will occur?

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market